Genomics Sponsored by Nvidia
New synthetic vaccine fights infectious disease with assistance from the data cloud
A new synthetic vaccine developed by researchers at the University of Bristol and the French National Centre for Scientific Research can be stored at warmer temperatures due to an engineered scaffold design. The details of the Chikungunya vaccine candidate are published in Science Advances on September 25.  Discuss
New research helps scientists understand the genetic cause of immune disease
Research published in Nature Genetics on September 23 helps narrow down the search for molecular drivers for immune disease which could result in the identification of new drug targets and development of new therapies illnesses such as asthma, multiple sclerosis, and arthritis.  Discuss
Exploring new tools with class 1 CRISPR systems
A biomedical engineering collaboration between researchers at Duke University and North Carolina State University explores new frontiers of CRISPR technology utilizing the less well-known class 1 CRISPR system. The study was published in Nature Biotechnology on September 23.  Discuss
New research suggests circular RNAs are important for cardiac healing
Researchers from the Lewis Katz School of Medicine at Temple University describe how circular RNA fills a critical role during tissue repair after heart attacks, due to a unique ability to absorb harmful molecules. The study was published September 20 in Nature Communications.  Discuss
Personalized disease models help to fight pediatric cancers
Researchers at Cedars-Sinai have developed a new rapid technique the genetically modify mice to produce personalized animal models, for example, pediatric glioma.  Discuss
Science Board Member Spotlight: Mona Batish, PhD
The Science Advisory Board is pleased to bring you a new series that focuses on the most essential part of the scientific process: you!
Germline genetic testing in breast cancer patients may lead to increased therapy options
Genetic testing for metastatic breast cancer patients may play a key role in identifying additional patients with increased risk and their response to targeted therapies.  Discuss
Vaccine in development against hypervirulent Klebsiella
Concerns arising over the development of hypervirulent strains of Klebsiella pneumoniae have led researchers to develop an entirely new vaccine to protect against the gram-negative bacteria. A team of researchers at Washington University School of Medicine in St. Louis and VaxNewMo (a startup based in St. Louis) designed the vaccine by genetically manipulating E. coli. The details of the prototype designed were published in the Proceedings of the National Academy of Sciences on August 27th.  Discuss
Genomic and microbial analyses reveal microbe independently degrades oil to gas
Methanoliparia, an archaea found in deep within oil reservoirs, may degrade oil to methane all by itself. Researchers from the Max Planck Institute for Marine Microbiology in Bremen, Germany and the MARUM, Centre for Marine Environmental Sciences provide genomic and microbial evidence of Methanoliparia’s ability to transform long-chain hydrocarbons to methane. The results were published in mBio on August, 20.  Discuss
The Parkinson’s Foundation launches large-scale genetic study, aiming to improve patient care and speed clinical trials
More than 10 million people worldwide are currently living with Parkinson’s disease (PD), a neurodegenerative disorder that impacts the dopamine-producing neurons in the brain. Scientists do not know exactly what causes PD, but they believe it is a combination of genetic and environmental factors. Nearly 10% to 15% of all PD cases are caused by genetic mutations. A new study aims to understand how the disease develops and how it can be treated or cured. This study, PD GENEration: Mapping the Future of Parkinson’s Disease is currently being conducted by the Parkinson’s Foundation.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter